Drug Trial Radar · NCT07667569
A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 6, 2026
Primary completion
Jun 28, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo. The main question this clinical trial aims to answer is: • Can ACT-777991 help return color to the skin of the face of adults with non-segmental vitiligo? Researchers will compare ACT-777991 to placebo (a look-alike inactive treatment that contains no medicine) to see if ACT-777991 works to treat non-segmental vitiligo. Trial participants will: * Take the trial intervention (either ACT-777991 or placebo) daily for 24 weeks. * Visit the clinic 7 times for check-up and tests.
Conditions
- Non-Segmental Vitiligo
Interventions
ACT-777991Drug
ACT-777991 tablets
PlaceboDrug
ACT-777991-matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main primary outcome measure: Percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) based on Blinded Independent Central Reading (BICR) at Week 24Time frame: Baseline; Week 24
- Supplementary primary outcome measure: Percentage change from baseline in F-VASI based on investigator assessment at Week 24Time frame: Baseline; Week 24
- Supplementary primary outcome measure: Percentage change from baseline in F-VASI at Week 4, 8 and 16Time frame: Baseline; Week 4, Week 8; Week 16
- Supplementary primary outcome measure: Achievement of F-VASI50 at Week 4, 8, 16 and 24Time frame: Baseline; Week 4; Week 8; Week 16; Week 24
- Supplementary primary outcome measure: Achievement of F-VASI75 at Week 4, 8, 16 and 24Time frame: Baseline; Week 4; Week 8; Week 16; Week 24
- Supplementary primary outcome measure: Achievement of F-VASI90 at Week 4, 8, 16 and 24Time frame: Baseline; Week 4; Week 8; Week 16; Week 24
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Vitiligo & Pigmentation Institute of Southern California
Los Angeles, California · Recruiting
Centrum Medyczne Angelius Provita
Katowice, Poland · Not yet recruiting
Medistica s.c.
Krakow, Poland · Not yet recruiting
Małopolskie Centrum Kliniczne
Krakow, Poland · Not yet recruiting
DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.
Osielsko, Poland · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.